BioCentury | Nov 10, 2020
Politics, Policy & Law

Bingham’s tenure with U.K. COVID vaccine task force drawing to a close

...has been reporting directly to Prime Minister Boris...
BioCentury | Nov 3, 2020
Politics, Policy & Law

U.K. review on COVID-19 racial disparities suggests biology could compound comorbidities, societal factors

...on how to reduce COVID-19 risks. Recommendations from Minister of Equalities Kemi Badenoch to Prime Minister Boris...
BioCentury | Oct 15, 2020
Politics, Policy & Law

U.K. joining regulatory consortium as Brexit deadline looms

...regulators. The move coincides with the arrival of Boris...
BioCentury | Sep 22, 2020
Politics, Policy & Law

Azar’s memo & biotech’s deals: a BioCentury podcast

...because there's a very conscious decision among some governmental leaders -- donald Trump is one, Boris...
BioCentury | Sep 7, 2020
Product Development

Bingham on U.K.’s flexible surge capacity in COVID-19 as foundation for future: a BioCentury audio interview

...SV Health Investors to chair the U.K. government’s Vaccine Taskforce, reporting directly to Prime Minister Boris...
BioCentury | May 16, 2020
Management Tracks

Bingham to lead U.K. push for a COVID-19 vaccine

...country deploying its industry expertise to combat COVID-19. Bingham will report directly to Prime Minister Boris...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

...With Prime Minister Boris Johnson now in the ICU, the urgency for answers to COVID-19 takes...
...March 20. Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus Stephen Hansen, Associate Editor COVID-19 cov19pol Boris...
BioCentury | Feb 21, 2020
Product Development

T regs are back - promising to do for autoimmunity what CAR Ts have done in cancer

Drug developers are giving regulatory T cells a second look as treatments for autoimmune disease. The difference this time is that they can leverage orthogonal benefits from CAR T cells in cancer, capitalizing on new...
BioCentury | Jan 14, 2020
Emerging Company Profile

Kyverna applies Tregs, CAR Ts to autoimmune diseases with $25M series A, Gilead deal

The team behind Cell Design Labs and its acquirers at Gilead are looking to capitalize on their T cell engineering platform again, bringing it into new indications with the launch of Kyverna. The company is...
BioCentury | Dec 13, 2019
Politics & Policy

U.K.’s life sciences sector dodges Labour bullet, concerns about relationship with EU remain

...and how quickly British patients will receive access to new therapies. The majority won by Boris...
Items per page:
1 - 10 of 65